» Articles » PMID: 23541541

Barriers to a Cure for HIV: New Ways to Target and Eradicate HIV-1 Reservoirs

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2013 Apr 2
PMID 23541541
Citations 165
Authors
Affiliations
Soon will be listed here.
Abstract

Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.

Citing Articles

Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.

Giron L, Liu Q, Adeniji O, Yin X, Kannan T, Ding J Nat Commun. 2024; 15(1):3035.

PMID: 38600088 PMC: 11006954. DOI: 10.1038/s41467-024-47279-4.


HIV Reservoirs and Treatment Strategies toward Curing HIV Infection.

Matsuda K, Maeda K Int J Mol Sci. 2024; 25(5).

PMID: 38473868 PMC: 10932120. DOI: 10.3390/ijms25052621.


HIV-Infected Hepatic Stellate Cells or HCV-Infected Hepatocytes Are Unable to Promote Latency Reversal among HIV-Infected Mononuclear Cells.

Lopez C, Freiberger R, Sviercz F, Quarleri J, Delpino M Pathogens. 2024; 13(2).

PMID: 38392872 PMC: 10893349. DOI: 10.3390/pathogens13020134.


A cohort-based study of host gene expression: tumor suppressor and innate immune/inflammatory pathways associated with the HIV reservoir size.

Dwivedi A, Gornalusse G, Siegel D, Barbehenn A, Thanh C, Hoh R PLoS Pathog. 2023; 19(11):e1011114.

PMID: 38019897 PMC: 10712869. DOI: 10.1371/journal.ppat.1011114.


Plasma Glycomic Markers of Accelerated Biological Aging During Chronic HIV Infection.

Giron L, Liu Q, Adeniji O, Yin X, Kannan T, Ding J bioRxiv. 2023; .

PMID: 37609144 PMC: 10441429. DOI: 10.1101/2023.08.09.551369.


References
1.
Stellbrink H, Hufert F, Tenner-Racz K, Lauer J, Schneider C, Albrecht H . Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2. Antivir Ther. 2000; 3(4):209-14. View

2.
Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R . Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012; 7(3):e33948. PMC: 3316511. DOI: 10.1371/journal.pone.0033948. View

3.
Mackall C, Fry T, Gress R . Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011; 11(5):330-42. PMC: 7351348. DOI: 10.1038/nri2970. View

4.
Schiffer J, Aubert M, Weber N, Mintzer E, Stone D, Jerome K . Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012; 86(17):8920-36. PMC: 3416169. DOI: 10.1128/JVI.00052-12. View

5.
Van Lint C, Emiliani S, Ott M, Verdin E . Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 1996; 15(5):1112-20. PMC: 450009. View